Date: 2017-01-05
Type of information: Development agreement
Compound: VEGF Kinoid
Company: Neovacs (France) Sunnybrook Research Institute (Canada)
Therapeutic area: Cancer - Oncology
Type agreement: development
Action mechanism: kinoid/immunotherapy product. A Kinoid is obtained by chemically linking the cytokine of interest to a foreign carrier protein, KLH ( Keyhole Limpet Hemocyanin), and then treating the resultant compound to inactivate the cytokine. These active immunotherapies have been designed to induce an antibody response (self-polyclonal antibodies) by the patient’s immune system that targets a particular over-expressed cytokine responsible for the pathogenesis and development of a given disease. The Kinoid technology can be applied in principle to any cytokine target.
Disease: colorectal cancer, ovarian cancer
Details: * On January 5, 2017, Neovacs announced its collaboration with Professor Robert Kerbel and his team at the Sunnybrook Research Institute of Toronto, Canada for preclinical development of Neovacs’ VEGF Kinoid, specifically to obtain the proof of concept for the treatment of colorectal and ovarian cancer. For these types of cancer the neutralization of VEGF-A could prevent tumor growth and development of metastases.
Financial terms:
Latest news:
